688506 百利天恒
已收盘 08-06 15:00:01
资讯
新帖
简况
百利天恒重启港股上市：第一季净亏7.8亿 去年配售37亿 市值1247亿
雷递网 · 20:20
百利天恒重启港股上市：第一季净亏7.8亿 去年配售37亿 市值1247亿
百利天恒最新公告：向香港联交所递交H股发行上市申请
证券之星 · 20:19
百利天恒最新公告：向香港联交所递交H股发行上市申请
四川百利天恒药业股份有限公司向港交所提交上市申请书
南方财经网 · 19:48
四川百利天恒药业股份有限公司向港交所提交上市申请书
百利天恒：创新药治疗一线广泛期小细胞肺癌全球多中心III期临床试验完成首例受试者给药
第一财经 · 17:22
百利天恒：创新药治疗一线广泛期小细胞肺癌全球多中心III期临床试验完成首例受试者给药
每周股票复盘：百利天恒（688506）HER2 ADC进入III期临床
证券之星 · 08-02
每周股票复盘：百利天恒（688506）HER2 ADC进入III期临床
研报掘金丨东北证券：首予百利天恒“增持”评级，核心产品III期临床全面铺开
格隆汇 · 07-31
研报掘金丨东北证券：首予百利天恒“增持”评级，核心产品III期临床全面铺开
百利天恒最新公告：注射用BL-B01D1（皮下注射）获临床试验批准
证券之星 · 07-30
百利天恒最新公告：注射用BL-B01D1（皮下注射）获临床试验批准
百利天恒：注射用T-Bren治疗胆道癌III期临床试验完成首例受试者入组
格隆汇 · 07-26
百利天恒：注射用T-Bren治疗胆道癌III期临床试验完成首例受试者入组
百利天恒(688506.SH)：注射用T-Bren(HER2 ADC)临床试验完成首例受试者入组
智通财经 · 07-26
百利天恒(688506.SH)：注射用T-Bren(HER2 ADC)临床试验完成首例受试者入组
每周股票复盘：百利天恒（688506）现大宗交易机构净买入1014.85万元
证券之星 · 07-26
每周股票复盘：百利天恒（688506）现大宗交易机构净买入1014.85万元
百利天恒跌6.27% 招商证券在历史大顶发研报强烈推荐
中金财经 · 07-24
百利天恒跌6.27% 招商证券在历史大顶发研报强烈推荐
百利天恒：伦康依隆妥单抗/宜泽康临床试验完成首例受试者入组
格隆汇 · 07-23
百利天恒：伦康依隆妥单抗/宜泽康临床试验完成首例受试者入组
百利天恒：伦康依隆妥单抗两项III期临床完成首例入组
财中社 · 07-23
百利天恒：伦康依隆妥单抗两项III期临床完成首例入组
7月21日百利天恒现1笔大宗交易 机构净买入1014.85万元
证券之星 · 07-21
7月21日百利天恒现1笔大宗交易 机构净买入1014.85万元
7月20日百利天恒涨7.41%，中欧医疗健康混合A基金重仓该股
证券之星 · 07-20
7月20日百利天恒涨7.41%，中欧医疗健康混合A基金重仓该股
百利天恒涨7.41%，开源证券二个月前给出“买入”评级
证券之星 · 07-20
百利天恒涨7.41%，开源证券二个月前给出“买入”评级
每周股票复盘：百利天恒（688506）食管癌适应症获批上市
证券之星 · 07-19
每周股票复盘：百利天恒（688506）食管癌适应症获批上市
食管鳞癌二线“无标准方案”困境终结？百利天恒创新药宜泽康获批给出新答案
每日经济新闻 · 07-17
食管鳞癌二线“无标准方案”困境终结？百利天恒创新药宜泽康获批给出新答案
百利天恒（688506）披露伦康依隆妥单抗/宜泽康食管癌适应症上市申请获得批准，7月16日股价下跌0.22%
证券之星 · 07-16
百利天恒（688506）披露伦康依隆妥单抗/宜泽康食管癌适应症上市申请获得批准，7月16日股价下跌0.22%
百利天恒：EGFR×HER3双抗药物适应症申请获批准
财中社 · 07-16
百利天恒：EGFR×HER3双抗药物适应症申请获批准
加载更多
公司概况
公司名称：
四川百利天恒药业股份有限公司
所属行业：
医药制造业
上市日期：
2023-01-06
主营业务：
四川百利天恒药业股份有限公司的主营业务是创新生物药业务和化药制剂、中成药制剂业务。公司的主要产品是创新生物药业务、化药制剂、中成药制剂。
发行价格：
24.70
{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":301.97,"timestamp":1785999601000,"preClose":289.91,"halted":0,"volume":2094111,"delay":0,"changeRate":0.0416,"floatShares":413000000,"shares":413000000,"eps":-3.1408,"marketStatus":"已收盘","change":12.06,"latestTime":"08-06 15:00:01","open":289.39,"high":301.97,"low":287.77,"amount":620000000,"amplitude":0.049,"askPrice":301.97,"askSize":0,"bidPrice":301.87,"bidSize":5,"shortable":0,"etf":0,"ttmEps":-3.1408,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786066200000},"marketStatusCode":5,"adr":0,"adjPreClose":289.91,"symbolType":"stock_kcb","openAndCloseTimeList":[[1785979800000,1785987000000],[1785992400000,1785999600000]],"highLimit":318.9,"lowLimit":260.92,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":412873817,"isCdr":false,"pbRate":22.09,"roa":"--","roe":"--","epsLYR":-2.61,"committee":-0.342466,"marketValue":124676000000,"turnoverRate":0.0051,"status":0,"afterMarket":{"amount":181182,"volume":600,"close":301.97,"buyVolume":0,"sellVolume":21240,"time":1786001637746,"indexStatus":"已收盘 08-06 15:30:00","preClose":289.91},"hkstockBrief":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1786003200000,"preClose":0,"halted":7,"volume":0,"delay":0,"premium":"-100.00"},"floatMarketCap":124676000000},"requestUrl":"/m/hq/s/688506/","defaultTab":"news","newsList":[{"id":"2657023639","title":"百利天恒重启港股上市：第一季净亏7.8亿 去年配售37亿 市值1247亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2657023639","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657023639?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:20","pubTimestamp":1786018817,"startTime":"0","endTime":"0","summary":"四川百利天恒药业股份有限公司日前重启IPO，并更新招股书，准备在港交所上市。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260806/6392164439947598114497040.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260806/6392164439947598114497040.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n34571/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["IPOS","91194","KCAI","BK0239","VXUS","BK4588","688506","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657202639","title":"百利天恒最新公告：向香港联交所递交H股发行上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2657202639","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657202639?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:19","pubTimestamp":1786018792,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司已于2026年8月6日向香港联交所递交境外上市外资股(H股)发行并上市的申请，并于同日在香港联交所网站刊登申请资料。该申请尚需取得证监会、香港证监会及香港联交所等监管机构的批准、核准或备案，存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600036460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","91194","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657393636","title":"四川百利天恒药业股份有限公司向港交所提交上市申请书","url":"https://stock-news.laohu8.com/highlight/detail?id=2657393636","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657393636?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:48","pubTimestamp":1786016880,"startTime":"0","endTime":"0","summary":"南方财经8月6日电，利弗莫尔证券显示，四川百利天恒药业股份有限公司向港交所提交上市申请书，联席保荐人为中信证券、Jefferies、中金公司、德意志银行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608063834046061.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608063834046061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","IPOS","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657681894","title":"百利天恒：创新药治疗一线广泛期小细胞肺癌全球多中心III期临床试验完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2657681894","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657681894?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:22","pubTimestamp":1786008136,"startTime":"0","endTime":"0","summary":"【百利天恒：创新药治疗一线广泛期小细胞肺癌全球多中心III期临床试验完成首例受试者给药】百利天恒公告，公司自主研发的创新生物药BL-M14D1联合PD-L1单抗对比含铂化疗联合PD-L1单抗治疗一线广泛期小细胞肺癌的全球多中心III期临床试验已于近日完成首例受试者给药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608063833940921.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608063833940921.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","MDTX","159992","IBBJ","III","MEDX","BK4134","91194","PSYK","BK0239","BK1161","BK1574","BMED","IBBQ","LNGR","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656316804","title":"每周股票复盘：百利天恒（688506）HER2 ADC进入III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2656316804","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656316804?lang=zh_cn&edition=full","pubTime":"2026-08-02 01:29","pubTimestamp":1785605350,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，百利天恒报收于298.0元，较上周的311.0元下跌4.18%。本周关注点来自公司公告汇总：注射用T-Bren在胆道癌III期临床完成首例受试者入组来自公司公告汇总：注射用BL-B01D1获准开展晚期实体瘤临床试验公司公告汇总四川百利天恒药业股份有限公司自主研发的注射用T-Bren在HER2表达的经含铂化疗治疗失败的局部晚期或转移性胆道癌患者中开展的III期随机对照临床试验已完成首例受试者入组。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","02615","688506","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655268358","title":"研报掘金丨东北证券：首予百利天恒“增持”评级，核心产品III期临床全面铺开","url":"https://stock-news.laohu8.com/highlight/detail?id=2655268358","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655268358?lang=zh_cn&edition=full","pubTime":"2026-07-31 15:14","pubTimestamp":1785482064,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0183","000686","BK0239","BK0276","688506","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655873611","title":"百利天恒最新公告：注射用BL-B01D1（皮下注射）获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655873611","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655873611?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:19","pubTimestamp":1785406775,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司近日收到国家药监局签发的《药物临床试验批准通知书》，自主研发的创新生物药注射用BL-B01D1(皮下注射)获批在晚期实体瘤患者中开展临床试验。注射用BL-B01D1（皮下注射）是在公司伦康依隆妥单抗/宜泽康（BLB01D1/iza-bren）的基础上开发的皮下制剂，有望缩短临床给药时长，提高给药便捷性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000029541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654063189","title":"百利天恒：注射用T-Bren治疗胆道癌III期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2654063189","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654063189?lang=zh_cn&edition=full","pubTime":"2026-07-26 15:59","pubTimestamp":1785052768,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","02615","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654639210","title":"百利天恒(688506.SH)：注射用T-Bren(HER2 ADC)临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2654639210","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654639210?lang=zh_cn&edition=full","pubTime":"2026-07-26 15:48","pubTimestamp":1785052138,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，公司自主研发的创新生物药注射用T-Bren在HER2表达的经含铂化疗治疗失败的局部晚期或转移性胆道癌患者中对比T-Bren与医生选择的化疗的III期随机对照临床试验已于近日完成首例受试者入组。据悉，T-Bren是一种靶向HER2的创新型ADC，具有同类最佳潜力，已在临床试验中展示出显著的抗肿瘤功效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","BK4080","IBBQ","91194","BK4231","02615","BMED","BK0239","IBBJ","MDTX","NETL","PSYK","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654052322","title":"每周股票复盘：百利天恒（688506）现大宗交易机构净买入1014.85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654052322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654052322?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:11","pubTimestamp":1784999469,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，百利天恒报收于311.0元，较上周的313.0元下跌0.64%。本周，百利天恒7月22日盘中最高价报353.0元。百利天恒当前最新总市值1284.04亿元，在化学制药板块市值排名3/149，在两市A股市值排名143/5200。来自公司公告汇总：伦康依隆妥单抗用于治疗胆道癌III期临床试验完成首例受试者入组。交易信息汇总7月21日百利天恒现1笔大宗交易，机构净买入1014.85万元。已有2项适应症获批上市，另有1项上市申请已获受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","91194","688506","02615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653700984","title":"百利天恒跌6.27% 招商证券在历史大顶发研报强烈推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2653700984","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653700984?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:44","pubTimestamp":1784882657,"startTime":"0","endTime":"0","summary":"中国经济网北京7月24日讯 百利天恒(688506.SH)今日收报311.00元，跌幅6.27%。\r\n\r\n 2025年9月8日，百利天恒股价盘中创上市以来高点414.02元。\r\n\r\n 招商证券股份有限公司研究员梁广楷、许菲菲、焦玉鹏2025年9月12日发布研报《百利天恒(688506)：从双抗ADC出发 多平台布局迈向国际领先的MNC》称，给予“强烈推荐”投资评级。\r\n\r\n 国泰海通证券股份有限公司研究员余文心、廖博闻2025年9月12日发布研报《百利天恒(688506)：WCLC上公布全球BIC数据 IZA-BREN有望冲击一线市场》称，维持增持评级。\r\n\r\n (责任编辑：徐自立)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260724/32317000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06099","BK1564","BK0188","BK0183","BK0239","BK1147","BK0010","600999","02615","BK0276","BK0012","688506","BK0028","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653374719","title":"百利天恒：伦康依隆妥单抗/宜泽康临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2653374719","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653374719?lang=zh_cn&edition=full","pubTime":"2026-07-23 20:03","pubTimestamp":1784808216,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688506","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653403937","title":"百利天恒：伦康依隆妥单抗两项III期临床完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2653403937","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653403937?lang=zh_cn&edition=full","pubTime":"2026-07-23 20:00","pubTimestamp":1784808000,"startTime":"0","endTime":"0","summary":"7月23日，百利天恒（688506）发布公告，公司自主研发的全球首创EGFR×HER3双抗ADC伦康依隆妥单抗/宜泽康（BL-B01D1/iza-bren）两项III期临床试验于近日分别完成首例受试者入组，涉及适应症为经内分泌治疗失败的晚期HR+HER2-乳腺癌和含铂化疗失败的局部晚期或转移性胆道癌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607233819152061.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607233819152061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","BK4134","BK0239","III","688506","02615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653514276","title":"7月21日百利天恒现1笔大宗交易 机构净买入1014.85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653514276","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653514276?lang=zh_cn&edition=full","pubTime":"2026-07-21 18:13","pubTimestamp":1784628817,"startTime":"0","endTime":"0","summary":"证券之星消息，7月21日百利天恒发生大宗交易，交易数据如下：大宗交易成交价格341.7元，成交2.97万股，成交金额1014.85万元，买方营业部为机构专用，卖方营业部为中国国际金融股份有限公司北京建国门外大街证券营业部。近三个月该股共发生1笔大宗交易，合计成交297.0手。该股在过去半年内已有共计1187.38万股限售解禁股上市，占公司总股本的2.88%。截至2026年7月21日收盘，百利天恒报收于341.7元，上涨1.64%，换手率0.68%，成交量2.82万手，成交额9.45亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100034496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","02615","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652029680","title":"7月20日百利天恒涨7.41%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652029680","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652029680?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:31","pubTimestamp":1784536312,"startTime":"0","endTime":"0","summary":"证券之星消息，7月20日百利天恒涨7.41%，收盘报336.2元，换手率0.77%，成交量3.18万手，成交额10.33亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共129家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为129.74亿元，最新净值1.926，较上一交易日下跌7.65%，近一年上涨2.86%。中欧医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000024671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159760","688506","BK0239","02615","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652968732","title":"百利天恒涨7.41%，开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2652968732","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652968732?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:31","pubTimestamp":1784536305,"startTime":"0","endTime":"0","summary":"今日百利天恒涨7.41%，收盘报336.2元。2026年4月29日，开源证券研究员余汝意,聂媛媛发布了对百利天恒的研报《Iza-bren商业化在即，多产品将开展全球注册临床》，该研报对百利天恒给出“买入”评级。研报中预计公司2026-2028年营收为24.76/22.99/30.76，当前股价对应PE分别为47.5/51.5/38.2倍，维持“买入”评级。此外，山西证券研究员邓周宇,魏赟,张智勇，东吴证券研究员朱国广近期也对该股发布了研报，同样给出“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000024669.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","02615","161027","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652237412","title":"每周股票复盘：百利天恒（688506）食管癌适应症获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2652237412","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652237412?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:34","pubTimestamp":1784396050,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，百利天恒报收于313.0元，较上周的310.9元上涨0.68%。本周，百利天恒7月16日盘中最高价报347.99元。该药为全球首创、全球首个且唯一获批上市的同类药物，中国为其首发上市国家。本次获批为该药在中国的第二项适应症。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","91194","688506","02615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652284485","title":"食管鳞癌二线“无标准方案”困境终结？百利天恒创新药宜泽康获批给出新答案","url":"https://stock-news.laohu8.com/highlight/detail?id=2652284485","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652284485?lang=zh_cn&edition=full","pubTime":"2026-07-17 23:57","pubTimestamp":1784303878,"startTime":"0","endTime":"0","summary":"7月16日，百利天恒（SH688506，股价313.00元，市值1292.30亿元）宣布，其全球首创EGFR×HER3双抗ADC（抗体偶联药物）药物伦康依隆妥单抗（iza-bren，商品名：宜泽康）获国家药监局批准第二项适应证，用于治疗既往经PD-1/PD-L1抑制剂联合含铂化疗治疗失败的复发性或转移性食管鳞癌（ESCC）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607173811420694.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607173811420694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MEDX","BK0239","BK1574","06978","91194","688506","159992","IBBQ","BK1161","02615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651440961","title":"百利天恒（688506）披露伦康依隆妥单抗/宜泽康食管癌适应症上市申请获得批准，7月16日股价下跌0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651440961","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651440961?lang=zh_cn&edition=full","pubTime":"2026-07-16 22:05","pubTimestamp":1784210725,"startTime":"0","endTime":"0","summary":"截至2026年7月16日收盘，百利天恒报收于332.83元，较前一交易日下跌0.22%，最新总市值为1374.17亿元。该药为全球首创、全球首个且唯一获批上市的同类药物，中国为其首发上市国家。本次获批为该药在中国的第二项适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600039970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","02615","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651449841","title":"百利天恒：EGFR×HER3双抗药物适应症申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651449841","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651449841?lang=zh_cn&edition=full","pubTime":"2026-07-16 19:09","pubTimestamp":1784200140,"startTime":"0","endTime":"0","summary":"7月16日，百利天恒（688506）发布公告，近日，公司收到国家药品监督管理局的《药品注册证书》，批准公司自主研发的全球首创EGFR×HER3双抗ADC药物伦康依隆妥单抗/宜泽康（BL-B01D1/iza-bren）用于食管癌晚期二线适应症的上市申请。这是全球首个且唯一获批上市的此类药物，同时也是在中国获批的第二项适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607163809191980.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607163809191980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","688506","BK0239","02615"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786022576408,"stockEarnings":[{"period":"1week","weight":-0.1003},{"period":"1month","weight":-0.1215},{"period":"3month","weight":0.0485},{"period":"6month","weight":0.0317},{"period":"1year","weight":-0.0237},{"period":"ytd","weight":-0.1027}],"compareEarnings":[{"period":"1week","weight":0.013},{"period":"1month","weight":-0.0403},{"period":"3month","weight":-0.0722},{"period":"6month","weight":-0.046},{"period":"1year","weight":0.0721},{"period":"ytd","weight":-0.0228}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7777人(较上一季度增加34.99%)","perCapita":"53089股","listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","registeredCapital":"41287万元","survey":" 四川百利天恒药业股份有限公司的主营业务是创新生物药业务和化药制剂、中成药制剂业务。公司的主要产品是创新生物药业务、化药制剂、中成药制剂。","listedPrice":24.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,688506,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}